Compare Altria Group Inc (MO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Zoetis Inc — how do they compare? Altria Group Inc trades at $71.13 (market cap $115.85B), while Zoetis Inc trades at $73.02 (market cap $29.57B). The key difference: Altria Group Inc is far larger — about 3.9× Zoetis Inc's market cap, and Altria Group Inc pays the higher dividend (6.4%). Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 154 Days and Zoetis Inc for 70 Days on average.
| MO | ZTS | |
|---|---|---|
Market Cap | $115.85B | $29.57B |
Volume | 6,934,962 | 4,128,093 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $147.53 |
52-Week Low | $54.72 | $69.09 |
Typical Hold Time | 154 Days | 70 Days |
Enterprise Value | $138.06B | $37.13B |
Dividend Yield | 6.4% | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $71.43, up 4.2% today, showing strong momentum despite mixed earnings history with two misses and one beat in recent quarters. The stock maintains a 6.6% dividend yield with 60 consecutive annual increases, supported by robust cash flow generation. Technical indicators show a bullish trend with current price near resistance at $71, while fundamentals reveal stable revenue around $20B annually but declining profit margins from 55.1% in 2024 to 34.5% in 2025.
MO presents a high-yield opportunity with strong cash flows but faces significant headwinds including negative shareholder equity, regulatory pressures, and declining cigarette volumes. Analyst consensus remains positive with 62% buy ratings and $69.71 price target, though the stock trades slightly above this target. The company's transition to smoke-free products remains critical for long-term sustainability amid changing consumer preferences.
Zoetis (ZTS) trades at $73.08, up 2.47% on the day, but remains in a bearish technical trend with support near $70. Fundamentally, the company reported strong 2025 results with $9.47B revenue, $2.67B net income, and robust margins, though recent quarters show mixed earnings performance. Analyst consensus is a Buy with a $87.33 price target, but sentiment is cautious due to U.S. pet care weakness and competitive pressures.
The stock offers value with a P/E of 11.67 and a 3% dividend yield, but near-term headwinds include declining U.S. companion animal sales and margin compression. Long-term growth prospects remain intact given industry leadership and international resilience, making it a contrarian opportunity for patient investors despite technical and competitive risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
